Overview

Eligibility

Design Details

Arms & Interventions

Outcome Measures

Trial Sites

Source: NCT06007846

Recruiting

A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer

Interventional

Phase 2/3

Inova Schar Cancer Institute

This is a single-site prospective study to describe efficacy endpoints of single agent memantine in patients with unresectable, locally advanced, or metastatic HCC otherwise not deemed candidates for intensive systemic therapy. In addition to the primary endpoint and multiple secondary efficacy endpoints, we will describe changes in quality of life on treatment over time.

Treatment Category

Other Drugs

Required Mutations

None

Trial Started

2023-07-31

Last Updated by Sponsor

2025-09-30

Estimated Completion

2026-07-31

Eligibility

Inclusion Criteria

1. Age 18 or older.

2. Patients have newly diagnosed and previously untreated, histologically or radiologically confirmed hepatocellular carcinoma with at least one lesion that is measurable by RECIST 1.1 criteria. A prior HCC lesion that was treated surgically or by radiation is allowed as long as it was at least 2 years or more from the current HCC diagnosis.

3. Patient's cancer must be deemed locally advanced and unresectable as per the consensus of the Inova Multidisciplinary Cancer Care Conference.

4. Patients must have a Child-Pugh cirrhosis score of B7 or greater and deemed not a candidate for aggressive systemic treatment.

5. Eastern Cooperative Oncology Group Performance Status of 0-2.

6. Patients must have adequate blood counts and organ function.

7. Memantine is harmful to the human fetus. For this reason, sexually active males with partners of childbearing potential must agree to use an accepted and effective method of contraception prior to study entry and for the duration of the study. Women of child bearing potential must have a negative serum pregnancy test result within 24 hours prior to initiation of study treatment. They must also agree to use agree to use an accepted and effective method of contraception prior to study entry and for the duration of the study.

8. Patients must demonstrate ability to understand and the willingness to sign a written informed consent document.

9. Men and women, regardless of race, ethnic group or sexual orientation are eligible for this study.

Exclusion Criteria

1. Patients with Child-Pugh A cirrhosis.

2. Female patients who are pregnant or breast-feeding.

3. Concomitant illness or history that would prevent adequate patient assessment or in the investigators' opinion pose an added risk for study participants.

4. Life-threatening intercurrent illness.

5. Anticipated poor compliance.

6. Subject is enrolled in a separate interventional clinical trial.

7. Active tuberculosis.

8. Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina.

9. Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC.

10. Uncontrolled tumor-related pain. Patients requiring pain medication must be on a stable regimen at study entry for at least 10 days prior to study entry.

11. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to initiation of study treatment.

12. Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases.

13. Patients undergoing other anti-cancer treatment. Palliative radiation for symptom control will be allowed while on protocol.

Do you think this trial is incorrectly appearing?

Design Details

AllocationN/A

Intervention ModelSingle Group Assignment

MaskingNone (Open Label)

Number to Enroll12

Arms & Interventions

Arms

Interventions

Type: Experimental

Description:

Interventions:

Namenda

Outcome Measures

Primary Outcome Measures

Patients Progression Free Survival at 6 months6 months from the start of treatment

The response and progression will be evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) guideline version 1.1. The progression of the disease is defined as at least a 20% increase in the sum of the Longest Diameter LD of target lesions, taking the smallest sum LD recorded as reference since the treatment started or the appearance of one or more new lesions or death due to disease without objective evidence of progression.

Secondary Outcome Measures

Change from baseline as assessed by the European Organization for Research and Treatment of Cancer (EORTC) quality-of-life questionnaire for cancer (EORTC QLQ-C30)2 years from the initial visit

The EORTC QLQ-C30 consists of 30 questions that assess five aspects of patient functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, pain), global health/QoL, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Each score is transformed onto a 0 to 100 point scale. For the symptom scales and single items, a higher score implies a high level of symptoms or problems. Previously published minimally important differences will be used to identify meaningful changes from baseline in each treatment group on the disease and treatment-related symptom scales.

Change from baseline as assessed by the European Organization for Research and Treatment of Cancer (EORTC-HCC18) over treatment2 years from the initial visit

The EORTC QLQ-HCC18 is a disease-specific measure which contains five multi-item symptom scales (fatigue, body image, jaundice, nutrition, and fever), and four single-item measures (shoulder pain, abdominal pain, abdominal swelling, and sex life) for a total of 18 questions with a recall period of the previous week. The EORTC QLQ-HCC18 module takes approximately 5 minutes to complete. All item responses are scored according to the EORTC guidelines for scoring.

Interested in participating?

Learn more about this trial and whether you may be eligible to participate.

Bookmark trial

Share Trial By Email

Download Trial

Do you think this trial is incorrectly appearing?

Report Trial

Download Trial

Trial Sites

This study has 2 trial sites

Inova Schar Cancer Institute
Fairfax, Virginia, US

Recruiting

Fairfax, Virginia, 22031 US

Inova Schar Cancer Institute

Not yet recruiting

Falls Church, Virginia, 22042 US

Inova Health Care Service

Loading Maps...